Uncategorized

Early Abortion Option and Women’s Health Care Advance Jeopardized

While mifepristone may be approved at the end of September, the FDA is currently discussing restrictions on the drug’s distribution that may severely limit women’s access to this medical breakthrough. The FDA is reportedly considering onerous and medically unnecessary restrictions that could drastically limit its distribution, possibly even threaten the safety of physicians, and ultimately derail the development of the drug’s non-abortion indications such as the treatment of ovarian cancer, fibroid tumors, meningioma, and endometriosis. Demand that mifepristone be approved without restrictions and sign this on-line petition! http://www.feminist.org/action/1_action.html